ExpreS2ion will present its ExpreS2 platform and pipeline at several key events in March and April 2020

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including Aktiespararna’s Aktiedagen, March 16 in Stockholm, Sweden, BIO-Europe Spring, March 23-25 in Paris, France, and World Vaccine Congress, April 6-8 in Washington, DC, USA.

During these and additional scientific and business partnering meetings, ExpreS2ion will present the advantages of the ExpreS2 platform for vaccine discovery, preclinical development and GMP production for clinical studies. Recent announcements include the launch of the new GlycoX-S2™ cell lines for improved immunogenicity and vaccine efficacy (link to October 24, 2019 press release), as well as the presentation of an ExpreS2ion-led European COVID-19 vaccine consortium for rapid clinical development of a new vaccine based on the ExpreS2 platform (link to February 24, 2020 press release).

CEO Bent Frandsen comments

“Our ExpreS2 platform is a leading tool for rapid development and GMP production of advanced and hard-to-express vaccines, as shown by its use in several high-profile malaria projects as well as in the recently announced COVID-19 vaccine development program backed by an European consortium that includes world-leading experts in all relevant areas of viral research and vaccine development. We are now actively pursuing opportunities to build our in-house pipeline of vaccine development projects, and we hope to meet potential collaboration partners as well as presenting our company to shareholders and other stakeholders at these events. I am excited to lead ExpreS2ion as we continue to build a strong company through the creation of world-class treatments for some of the most important medical challenges of our time.”

ExpreS2ion will participate in the following event activities in March and April, 2020:

Aktiespararna’s Aktiedagen, March 16, Stockholm, Denmark

See the company presentation by our CEO, Bent U. Frandsen, at this investor event either online or attend the meeting by reserving a seat at Aktiespararna's website.

BIO-Europe Spring, March 23-25, Paris, France
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at BIO-Europe’s website.

World Vaccine Congress (WVC), April 6-8, Washington, DC, USA
To learn more about ExpreS2 and our novel GlycoX-S2™ cell lines, see Dr. Wian de Jongh, CSO, present our proven, effective solutions for recombinant protein development and production. Pre-arrange meetings via email on info@expreS2ionbio.com. More information at WVC’s website.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

For further information about ExpreS2ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail:
buf@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.

About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.

Subscribe